Reston, VA (October 24, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
New PET Tracer Shows Promise for Early Detection of Immunotherapy Response
Researchers tested a new PET imaging agent, ¹⁸F-MeFAMP, designed to distinguish true tumor response from inflammation during immune checkpoint inhibitor (ICI) therapy. In mouse models, ¹⁸F-MeFAMP clearly differentiated responders from nonresponders, unlike standard ¹⁸F-FDG scans. The tracer's low background uptake in normal organs suggests potential for more accurate early treatment assessment.
Understanding What Affects Accuracy in Amyloid PET Quantification
As amyloid PET imaging increasingly relies on the Centiloid scale, researchers examined how sample size and image resolution influence measurement accuracy. Using multiple tracers and analysis pipelines, they found that smaller calibration datasets and lower image resolution introduce modest errors—especially in scans with high amyloid burden—highlighting key factors for consistent Alzheimer's imaging results.
Imaging the Immune System: Tracking Cytokines with Nuclear Medicine
Cytokines are key immune messengers that shape how the body responds to disease and infection. Traditional lab tests struggle to capture their rapid, complex activity. This review highlights emerging PET and SPECT imaging tools that visualize cytokines in real time, offering new ways to study and monitor immune-driven diseases and treatments.
New PSMA PET Tracer Improves Noninvasive Prostate Cancer Staging
A review of 19 studies found that ¹⁸F-PSMA-1007 PET/CT is a highly accurate, noninvasive tool for staging prostate cancer. Compared with tissue-based diagnosis, it showed strong sensitivity and specificity for detecting tumor spread within and beyond the prostate, offering a single imaging approach for assessing local, nodal, and distant disease before treatment.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
